Goldman Sachs Reiterates Buy Rating on Avidity Biosciences (RNA)

October 3, 2024 9:54 AM EDT Send to a Friend
Goldman Sachs analyst Corinne Johnson reiterated a Buy rating and $59.00 price target on Avidity Biosciences (NASDAQ: RNA).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login